

CLIENT & SAMPLE INFORMATION

Client	Glacier Aminos	Analysis Date	07/14/2026
Product Name	BPC-157/TB-500	Form / Matrix	Nasal Spray
Lot / Batch	BPTBSPR-01		

This Certificate of Analysis reports the qualitative identity and the measured concentration of the declared peptide active(s) within the submitted nasal-spray formulation. Identity was confirmed by reverse-phase HPLC with UV detection against a reference standard; concentration was determined by quantitative HPLC-UV against a reference standard. Concentration values reflect the submitted solution as received.

PEPTIDE IDENTITY & CONCENTRATION

Each declared active was screened by HPLC-UV against a reference standard. Identity is confirmed by retention-time match to the reference standard within the method's analytical tolerance; content is quantified against a reference standard and reported as total mg.

Declared Active	Listed (mg)	Result (mg)	Status
BPC-157	30	31.54	PASS
TB-500	30	30.84	PASS

Method: HPLC-UV quantitation with reference-standard identity confirmation. 2 declared actives screened, confirmed present, and quantified.

ADDITIONAL QUALITY SCREENS

ENDOTOXIN SCREEN

Method	LAL (USP <85>)
Limit	<= 0.5 EU/mL
Result	< 0.10 EU/mL
Status	PASS

STERILITY / MICROBIAL SCREEN

Method	Rapid Sterility
Specification	No Growth
Result	No microbial growth detected
Status	PASS

TESTING METHODOLOGY & SUBMITTED SAMPLE

Peptide Identity & Concentration in Nasal-Spray Matrix

Each declared active was analyzed directly from the submitted nasal-spray solution. Identity was established by reverse-phase HPLC with UV detection, matching the retention time of each declared peptide against an external reference standard within the method's analytical tolerance window. Content was determined by quantitative HPLC-UV against an external reference standard and reported as total mg of the submitted solution.

Sample Preparation: Aliquots of the submitted solution were diluted in HPLC-grade solvent, filtered through a 0.22 µm PTFE membrane, and injected directly onto the analytical column. No derivatization was performed.

Scope & Limitations: This report establishes qualitative identity and measured concentration of the declared active(s) in the submitted solution. It does not establish biological activity, finished-product stability, sterility beyond any screen reported above, delivered dose accuracy of the pump/actuator, or fitness for any particular use.



CONFORMANCE STATEMENT

Identity confirmed. The declared peptide actives — **BPC-157, TB-500** — were detected in the submitted nasal-spray formulation and quantified as reported above. This certificate attests to identity and measured concentration of the submitted solution only.

